Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RBP4 | P02753 | 2/20 | 0.31 |
| ▸ | KCNA1 | Q09470 | 1/20 | 0.31 |
| ▸ | KCNAB1 | Q14722 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31017480 | 0.81 | POLB (0.41) | POLBLMNAKMT2ACYP2D6CYP2C19 | |
| SCHEMBL16791886 | 0.79 | HTT (0.44) | POLBLMNAKMT2A | |
| SCHEMBL31017504 | 0.78 | TDP1 (0.46) | POLBLMNAKMT2ATDP1KDM4E | |
| SCHEMBL15931753 | 0.76 | HTT (0.53) | LMNAKMT2ACYP2C19 | |
| SCHEMBL28831745 | 0.76 | POLB (0.42) | POLBLMNAKMT2ATDP1 | |
| SCHEMBL4030616 | 0.74 | POLB (0.68) | POLBKMT2ATDP1 | |
| SCHEMBL3224580 | 0.71 | POLB (0.39) | POLBKMT2A | |
| SCHEMBL5238596 | 0.69 | KMT2A (0.72) | POLBKMT2ATDP1CYP2D6KDM4E | |
| SCHEMBL1775906 | 0.69 | SMN1; SMN2 (0.58) | CYP2D6CYP2C19 | |
| SCHEMBL31017493 | 0.68 | L3MBTL3 (0.47) | POLBKMT2ACYP2D6CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029539-B1 | N-(piperidinyl)-urea derivatives as inhibitors of soluble epoxide hydrolase for the treatment of e.g. hypertension or inflammations | UNIV CALIFORNIA (US) | 2016-06-29 | — | — | EP | disclosed |
| US-9029550-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130274476-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | UNIV CALIFORNIA (US) | 2013-10-17 | — | — | US | disclosed |
| US-8501783-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-08-06 | — | — | US | disclosed |
| US-20130137726-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-05-30 | — | — | US | disclosed |
| US-8188289-B2 | Conformationally restricted urea inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-05-29 | — | — | US | disclosed |
| WO-2010053829-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2010-05-14 | — | — | WO | disclosed |
| US-20100063583-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ARETE THERAPEUTICS, INC. | 2010-03-11 | — | — | US | disclosed |
| WO-2010025043-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ARETE THERAPEUTICS, INC. (US) | 2010-03-04 | — | — | WO | disclosed |
| EP-2124917-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | Arete Therapeutics, Inc. (US) | 2009-12-02 | — | — | EP | disclosed |
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009129501-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2009-10-22 | — | — | WO | disclosed |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC | 2009-08-06 | — | — | US | disclosed |
| EP-2029539-A1 | PIPERIDINYL, INDOLYL, PIRINIDYL, MORPHOLINYL AND BENZIMIDAZOLYL UREA DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE FOR THE TREATMENT OF HYPERTENSION, INFLAMMATIONS AND OTHER DISEASES | The Regents of the University of California (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080221105-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080207908-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | ARETE THERAPEUTICS, INC | 2008-08-28 | — | — | US | disclosed |
| WO-2008094862-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | ARETE THERAPEUTICS, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008094869-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | ARETE THERAPEUTICS, INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-27 | — | — | US | disclosed |
| WO-2007106525-A1 | PIPERIDINYL, INDOLYL, PIRINIDYL, MORPHOLINYL AND BENZIMIDAZOLYL UREA DERIVATIVES AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE FOR THE TREATMENT OF HYPERTENSION, INFLAMMATIONS AND OTHER DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270452-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF SMOOTH MUSCLE DISORDERS | EPHX1, PTGIS, PDE3A | POLB 1740/4885LMNA 2614/4885KMT2A 2825/4885 |
| US-20100063583-A1 | USE OF SOLUBLE EPOXIDE HYDROLASE INHIBITORS IN THE TREATMENT OF INFLAMMATORY VASCULAR DISEASES | ALOX15B, ALOX15, ALOX12 | POLB 1721/4885LMNA 1688/4885KMT2A 4584/4885 |
| US-20070225283-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | POLB 2136/4885LMNA 3843/4885KMT2A 3394/4885 |
| US-20080221105-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | EPHX1, NCEH1, PNLIP | POLB 2388/4885LMNA 2686/4885KMT2A 3363/4885 |
| US-20090197916-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS FOR TREATMENT OF METABOLIC SYNDROME AND RELATED DISORDERS | EPHX1, NCEH1, PNLIP | POLB 2388/4885LMNA 2686/4885KMT2A 3363/4885 |
| US-20080207908-A1 | PROCESSES FOR THE PREPARATION OF PIPERIDINYL-SUBSTITUTED UREA COMPOUNDS | UMPS, CPS1, NISCH | POLB 101/4885LMNA 1436/4885KMT2A 2447/4885 |
| US-20130274476-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | POLB 2145/4885LMNA 3899/4885KMT2A 3238/4885 |
| US-20130137726-A1 | CONFORMATIONALLY RESTRICTED UREA INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, EPHX2, NCEH1 | POLB 2136/4885LMNA 3843/4885KMT2A 3394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.